Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Malone Wealth Ventures LLC, a U.S. registered investment adviser, filed Schedule 13G/A (Amendment No. 5) on 10 July 2025 disclosing a significant position in Quantum Biopharma Ltd. (QNTM). The firm reports beneficial ownership of 735,148 Class B subordinate voting shares, equating to 19.4 % of the outstanding class. Malone retains sole voting power over 103,601 shares and sole dispositive power over the full stake; no shares are subject to shared voting or dispositive power. The difference indicates that most shares are held for advisory clients who keep voting rights while Malone manages disposition.
The filer certifies the shares were acquired in the ordinary course of business and not to influence control. No subsidiaries or group members are involved, and no single client holds more than 5 % of the class. Quantum Biopharma’s headquarters remain at 55 University Ave., Suite 1003, Toronto, Ontario.
This near-20 % holding positions Malone as a major stakeholder, improving institutional visibility for Quantum Biopharma and potentially stabilising the shareholder base. Investors should monitor upcoming ownership updates, as any move above the 20 % threshold or a switch to Schedule 13D could signal a change in strategic intent.
Malone Wealth Ventures LLC filed Amendment No. 4 to Schedule 13G on 10 July 2025, reporting a sizeable passive stake in Quantum Biopharma Ltd. (QNTM).
- Ownership level: The filing discloses beneficial ownership of approximately 19–20 % of QNTM’s common shares, equating to 689,421–735,148 shares depending on the section cited.
- Voting vs. dispositive power: Malone holds sole voting power over 103,601–109,765 shares but sole dispositive power over the full reported amount; no shared powers are reported.
- Filing status: The adviser filed on a Schedule 13G, indicating the position is held in the ordinary course of business and not with the intent to influence control of the issuer.
- Entity details: Malone Wealth Ventures LLC is a U.S.-based registered investment adviser; its clients ultimately benefit from dividends or sale proceeds, and no single client exceeds the 5 % threshold.
- Signatory: Kevin M. Malone, President & CEO, signed the certification.
The filing confirms that a professional asset manager has accumulated a near-20 % stake, potentially lending market confidence and increasing the free-float concentration, while remaining a passive investor. Investors should note the internal inconsistency between share counts (689,421 vs 735,148) and the consequent slight difference in reported ownership percentage (19.9 % vs 19.4 %).
Malone Wealth Ventures LLC ("MWV") has filed Amendment No. 3 to Schedule 13G for Quantum Biopharma Ltd. (QNTM) dated 10 July 2025. The investment adviser, organized in the United States, now reports beneficial ownership of 735,148 common shares—approximately 19.4 % of Quantum Biopharma’s outstanding stock.
MWV discloses sole voting power over 103,601 shares and sole dispositive power over the full 735,148-share position; no shares are subject to shared voting or dispositive authority. The filing is made on Schedule 13G, signalling the position is considered passive under SEC rules. MWV affirms the holdings were acquired in the ordinary course of business and not for the purpose of influencing control, in line with Rule 13d-1(b)(1)(ii)(E) applicable to investment advisers.
Clients of MWV retain the economic rights to dividends or sale proceeds, but no single client holds more than 5 % of the class. The certification section confirms the accuracy and completeness of the disclosure, with the document signed by President and CEO Kevin M. Malone.
Malone Wealth Ventures LLC filed an Amendment No. 1 to Schedule 13G disclosing its ownership in Quantum Biopharma Ltd. (QNTM) common stock as of 11 June 2025.
- Aggregate beneficial ownership: 689,421 shares, representing 19.9 % of the outstanding class.
- Sole voting power: 109,765 shares (16 % of the firm’s economic stake), indicating limited influence on shareholder votes.
- Sole dispositive power: 689,421 shares; the firm can sell or otherwise dispose of the entire position without third-party consent.
- Shared voting/dispositive power: 0 shares.
- The shares are held in the ordinary course of business; Malone Wealth Ventures certifies it is not seeking to influence control of Quantum Biopharma.
- The filing is made under Rules 13d-1(b), 13d-1(c) and 13d-1(d), affirming the filer’s status as, among other categories, an investment adviser and parent holding company.
- Clients of Malone Wealth Ventures are the economic beneficiaries of the shares, but no individual client holds more than 5 % of the class.
This near-20 % stake makes Malone Wealth Ventures the largest known passive holder of QNTM, signalling meaningful external confidence while keeping governance influence muted due to the relatively low voting power disclosed.
Quantum BioPharma Ltd. (symbol QNTM) filed a routine Form 6-K on 27 June 2025. The filing’s sole purpose is to furnish a press release, dated the same day, as Exhibit 99.1. No financial statements, earnings data, or transaction details are included in this submission. The document confirms the company continues to file its annual report on Form 20-F and bears the signature of Chief Financial Officer Donal Carroll.
Schedule 13D/A (Amendment 3) – Quantum Biopharma Ltd. (QNTM)
Malone Wealth Ventures LLC ("MWV") and its President & CEO Kevin Malone report beneficial ownership of 610,371 common shares, representing 17.8 % of Quantum Biopharma’s outstanding stock. MWV has sole dispositive power over the entire stake and sole voting power over 52,265 shares.
The position was built through (i) open-market purchases using discretionary client funds and (ii) 90,000 shares granted to Kevin Malone for advisory services (30,000 initial grant plus 60,000 continuation grant).
On 23 June 2025, MWV executed 21 exchange transactions, mainly buys between $22.18–$29.19 and one sale of 5,000 shares at $22.549, indicating ongoing accumulation around a volatile price range.
The securities are held for investment purposes; however, Malone’s role as Advisor to the Board means the reporting persons "may be deemed" to seek influence over strategic direction, financing, capitalization and governance. MWV states it may buy or sell additional shares depending on market conditions.
No legal proceedings are disclosed, and both reporting persons are U.S. citizens/entities.
Malone Wealth Ventures LLC has filed a Schedule 13D/A amendment disclosing a 17% ownership stake (580,806 shares) in Quantum Biopharma. The filing reveals significant recent share accumulation through multiple transactions between June 13-20, 2025, with purchase prices ranging from $19.10 to $37.59 per share.
Key details:
- Kevin Malone serves as Advisor to Quantum Biopharma's Board of Directors
- Received 90,000 shares in total as compensation (30,000 initial grant plus 60,000 additional)
- Has sole voting power over 52,265 shares and sole dispositive power over 580,806 shares
- Shares acquired through client funds (Malone Wealth Ventures) and board advisor compensation
The filing indicates potential influence over company control, with Malone participating in discussions regarding strategic direction, financing, capitalization, and corporate governance. The advisory agreement was established on April 15, 2025, with additional RSUs available based on performance goals.